Neimeth (NEIMETH)

Currency in NGN
8.95
-0.95(-9.60%)
Closed·
NEIMETH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.9510.80
52 wk Range
3.3016.15
Key Statistics
Bid/Ask
8.95 / 9.45
Prev. Close
9.9
Open
9.9
Day's Range
8.95-10.8
52 wk Range
3.3-16.15
Volume
6.51M
Average Volume (3m)
7.45M
1-Year Change
148.6111%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NEIMETH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.30
Upside
+26.26%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.30
(+26.26% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
05/05/2026
EPS / Forecast
0.03 / --
Revenue / Forecast
1.75B / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.23%
Dividend Yield
-
Industry Median 0.73%
Annualised payout
-
Paid annually
5-Years Growth
-
Growth Streak

Neimeth (NEIMETH) Income Statement & Profits

Compare NEIMETH to Peers and Sector

Metrics to compare
NEIMETH
Peers
Sector
Relationship
P/E Ratio
43.0x−4.0x−0.4x
PEG Ratio
0.200.080.00
Price/Book
15.4x1.3x2.6x
Price / LTM Sales
5.3x1.7x3.0x
Upside (Analyst Target)
14.1%44.1%58.3%
Fair Value Upside
Unlock8.8%8.3%Unlock

Neimeth International Pharmaceuticals Plc manufactures and markets pharmaceutical and animal health products in Nigeria and Ghana. It provides health care, ethical, and veterinary related products; and poultry and animal range of anthelmintic products, as well as production enhancing medicaments. The company was formerly known as Pfizer Inc. and changed its name to Neimeth International Pharmaceuticals Plc. In 1997. Neimeth International Pharmaceuticals Plc was incorporated in 1957 and is based in Lagos, Nigeria.

Employees
212
Market
Nigeria

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
2.25B52.72%22.30B
Public Companies & Retail Investors
2.02B47.28%20.00B
Total
4.27B100.00%42.3B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Clinoscope Services Limited25.00%1,068,276,37510,575,936
Helko Nigeria Limited10.11%431,805,2224,274,872

People Also Watch

12.850
MANSARD
0.00%
8.75
ELLAHLA
-2.78%
2.980
CUTIX
-0.33%
3.25
JAPAULGOLD
+3.50%
20.650
CWG
0.00%

FAQ

What Is the Neimeth (Lagos: NEIMETH) Share Price Today?

The Neimeth stock price today is 8.95 NGN.

What Stock Exchange Does Neimeth (NEIMETH) Trade On?

Neimeth is listed and trades on the Lagos.

What Is the Ticker (Stock Symbol) for Neimeth?

The stock symbol (also called a 'ticker') for Neimeth is "NEIMETH."

What Is the Current Neimeth Market Capitalisation?

As of today, Neimeth (Lagos: NEIMETH) market cap is 38.24B NGN.

What Is Neimeth's (NEIMETH) Earnings Per Share (TTM)?

The Neimeth EPS is currently 0.23 (Trailing Twelve Months).

Is NEIMETH a Buy or Sell From a Technical Analyst Perspective?

Based on today's Neimeth moving averages and other technical indicators, the daily buy/sell signal for NEIMETH stock is Strong Sell.

How Many Times Has Neimeth Stock Split?

Neimeth has split 6 times. (See the NEIMETH stock split history page for full effective split date and price information.)

How Many Employees Does Neimeth Have?

Neimeth has 212 employees, based on their latest Companies House report.

What is the current trading status of Neimeth (Lagos: NEIMETH)?

As of 19/06/2026, Neimeth (NEIMETH) is trading at a share price of 8.95 NGN, with a previous close of 9.90 NGN. The stock has fluctuated within a day range of 8.95 NGN to 10.80 NGN, while its 52-week range spans from 3.30 NGN to 16.15 NGN.

What Is Neimeth (NEIMETH) Price Target According to Analysts?

The average 12-month price target for Neimeth is 11.30 NGN, with a high estimate of 11.3 NGN and a low estimate of 11.3 NGN. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +26.26% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.